Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.

Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same period in 2010.  Increased operating expenses for the fourth quarter of 2011 and for the full calendar year compared to the same periods in 2010 are primarily due to increased research and development expenses associated with our Phase 2b PEARL-SC clinical study in patients with Systemic Lupus Erythematosus, or lupus, and our VISTA-16 clinical study in patients with Acute Coronary Syndrome, or ACS.

Anthera ended the fourth quarter of 2011 with approximately $67.4 million in cash and cash equivalents and short-term investments.  This is compared to $93.3 million in cash and cash equivalents and short-term investments for the third quarter ended September 30, 2011.

In conjunction with the release of the fourth quarter 2011 financial report, Anthera will host a conference call at 1 p.m. Eastern Time today, February 21, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 47038854. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854.  The audio replay will be available until February 28, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • In December 2011, the VISTA-16 Data Safety Monitoring Board (
    '/>"/>

    • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... CLARA, Calif. , June 19, 2013 /PRNewswire/ ... control solutions for life sciences process applications, announced ... glass bioreactors for upstream cell culture and fermentation.  ... a new product family of Finesse bioreactors and ... and cGMP applications.  They are fully compatible with ...
    (Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
    (Date:6/19/2013)... , June 19, 2013 BD Biosciences, a ... BDX ), a leading global medical technology company, today announced ... , the latest in its line of high-performance research flow ... delivers high-performance multicolor analysis with the most compact footprint in ... cm) and a height of 30" (76.2 cm). Recognizing that ...
    Breaking Medicine Technology:Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Drug Patent Watch 2Drug Patent Watch 3New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
    ... Feb. 28, 2012 Landauer, Inc. (NYSE: LDR) ... quarterly cash dividend of $0.55 per share for the second ... 3, 2012, to shareholders of record on March 9, 2012. ... global provider of technical and analytical services to determine occupational ...
    ... N.C., Feb. 28, 2012  In an effort to maximize ... and biotech market research leaders must constantly evaluate the ... executives need to understand the optimal balance of external ... productivity in the quickly changing healthcare industry. ...
    Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
    (Date:6/20/2013)... 20, 2013 In an article found ... recently, that can show similarities between an addiction to ... explain the current global obesity pandemic. , To test ... just as one can be addicted to drugs, Dr ... Science at the University of Guelph, has studied the ...
    (Date:6/20/2013)... (PRWEB) June 20, 2013 Creighton ... Education Community Service Honor Roll – the highest federal ... commitment to volunteering, student- service learning and civic engagement ... presented by the Corporation for National and Community Service, ... sixth for Creighton. “Our foundation at Creighton is based ...
    (Date:6/19/2013)... 20, 2013 Everyone is looking for ways to ... way to do so. It is called Skin Brushing . ... 5 minutes per day - to improve health and skin quality. ... health. How? , Skin Brushing improves general health because:, ... aids the lymphatic system to drain toxins , it ...
    (Date:6/19/2013)... 20, 2013 Shreya Rangarajan of Roland ... youth summit on the future of medicine. , ... Global Youth Summit on the Future of Medicine and ... School and the state of Maryland at the Summit. ... practice in an environment hard to imagine just a ...
    (Date:6/19/2013)... (PRWEB) June 20, 2013 A man returning from ... he used to be. In his debut book titled RED DANCER ... veteran who immerses himself back home, looking for the right place ... De Los Angeles, former marine from the Vietnam War, returns to ... the edge off his PTSD. Wings, a wealthy acquaintance from a ...
    Breaking Medicine News(10 mins):Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2
    ... Tender Offer Connected with Previously Announced Plans to Separate Medical ... Technology and Funeral Services Businesses, ... ) (the "Company") announced today that it has,commenced a cash ... percent Senior Notes due 2009 (CUSIP No. 431573AD6), of which ...
    ... 29 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... its fourth quarter and full year 2007 financial,results on ... and is,hosting a conference call and webcast to discuss ... Management will discuss financial results for the,fourth quarter and ...
    ... With the State of,Minnesota facing a $935 million ... to ensure that the health and independence of,the ... "On the one hand, legislators are discussing meaningful ... chronic conditions, and on the,other, we expect the ...
    ... The Board of,Directors of Schering-Plough Corporation (NYSE: ... for Ian McInnes, Ph.D., to senior vice,president and ... vice,president, Global Supply Chain. The change reflects the ... that now includes operations from,Organon BioSciences N.V., acquired ...
    ... the disease , , FRIDAY, Feb. 29 (HealthDay News) -- While ... also play a major role in the development of the ... on more than 40,000 twins born in 1958 or earlier, ... risk for chronic bronchitis and that 14 percent of the ...
    ... Feb. 29 The American people,through the ... and,a consortium of four partners, will assist ... implement HIV/AIDS prevention, malaria and child,survival programs. ... project,will involve district stakeholders, the private sector ...
    Cached Medicine News:Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:USAID Implements Behavior Change and Social Marketing Program in Rwanda 2
    ... LASIK Marker Has Two ... Evenly Distributed Marks, Providing ... Lamellar Flap To Insure ... Marks Prevent Inadvertent Placement ...
    ... Be Used With The Gills Nomograms. 6mm ... Cornea For Making Limbal Relaxing Incisions., , 8-12108-5 ... Nomograms. 6mm & 8mm Chord Length Radials Placed ... Inner Circle Assists In Sizing A Precise Capsulorrhexis ...
    ... Manually Dilate A Small Pupil With Greater ... Safety By Allowing The Iris Hooks To ... The Plane Of The Anterior Capsule, Thus ... Pupil Stretching Is Also Maximized, With The ...
    ... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture., ... Providing Unobstructed Around-The-Clock Access To The ...
    Medicine Products: